39742-60-4

Basic information

• Product Name: 1-Phenethyl-4-piperidone
• Synonyms: 1-(2-phenylethyl)-4-piperidinon;1-(beta-phenethyl)piperidone;1-phenethyl-4-piperidon;N-(2-PHENYLETHYL)-4-PIPERIDONE;N-(2-PHENETHYL)-4-PIPERIDONE;LABOTEST-BB LT00159981;1-PHENETHYL-4-PIPERIDONE;1-(2-PHENETHYL)-4-PIPERIDONE
• CAS NO: 39742-60-4
• Molecular Formula: C₁₃H₁₇NO
• Molecular Weight: 203.28
• EINECS: 254-613-5
• Product Categories: Piperidine;API intermediates;Benzenes;Building Blocks;Heterocyclic Building Blocks;Piperidones;Aromatics;Heterocycles;Intermediates;Intermediates & Fine Chemicals;Pharmaceuticals;research chemical;pharmaceutical intermediates
• Mol File: 39742-60-4.mol

Chemical Properties

• Melting Point: 57-60 °C(lit.)
• Boiling Point: 341.6°C (rough estimate)
• Flash Point: 144.2 °C
• Appearance: yellow-brown crystalline powder
• Density: 1.0156 (rough estimate)
• Vapor Pressure: 0.0563mmHg at 25°C
• Refractive Index: 1.5400 (estimate)
• Storage Temp.: Store below +30°C.
• Solubility: ethanol: soluble, clear to hazy, light yellow to yellow (50 mg/m
• PKA: 8.02±0.20(Predicted)
• BRN: 130302
• CAS DataBase Reference: 1-Phenethyl-4-piperidone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Phenethyl-4-piperidone(39742-60-4)
• EPA Substance Registry System: 1-Phenethyl-4-piperidone(39742-60-4)

Safety Data

• Hazard Codes: Xn,C,F
• Statements: 22-34-11
• Safety Statements: 22-24/25-45-26-36/37/39-16
• RIDADR: 2811
• WGK Germany: 3
• RTECS: TN8990300
• F: 10
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 39742-60-4(Hazardous Substances Data)

Usage

Chemical Properties

YELLOW-BROWN CRYSTALLINE POWDER

Uses

1-Phenethyl-4-piperidone was used in the preparation of phenethyl derivative of the propanamide. It was also used to synthesize l-Phenethylazacycloheptan-4-one.

References

https://en.wikipedia.org/wiki/N-Phenethyl-4-piperidinone Jones, T. S, et al. "Nonpharmaceutical Fentanyl-Related Deaths — Multiple States, April 2005–March 2007." Morbidity & Mortality Weekly Report 57.29(2008): 793-796. https://www.alfa.com/en/catalog/B21146/

InChI:InChI=1/C9H17NO/c1-8(2)7-10-5-3-9(11)4-6-10/h8H,3-7H2,1-2H3

Upstream product

• 38129-46-3 dimethyl β,β'-(2-phenylethylamino)dipropionate 
• 57958-47-1 3,3'-phenethylimino-di-propionic acid diethyl ester 
• 24089-69-8 8-Phenethyl-1,4-dioxa-8-aza-spiro[4.5]decane; hydrochloride 
• 16771-89-4 1-(3-phenylethyl)-4-piperidone ethylene ketal 
• 3518-76-1 (RS)-(+/-)-1-phenethylpiperidin-4-ol 
• 41979-39-9 4-piperidone hydrochloride 
• 122-78-1 phenylacetaldehyde 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 103-63-9 1-phenyl-2-bromoethane 
• 66670-11-9 methyl 1-(2-phenylethyl)-4-oxo-piperidine-3-carboxylate 
• 64-04-0 phenethylamine 
• 626-64-2 pyridin-4-ol 
• 20020-27-3 2-phenylethyl mesylate 
• 5382-16-1 4-HYDROXYPIPERIDINE 

Downstream Products

• 101745-47-5 4,4-diethoxy-1-phenethyl-piperidine 
• 109694-60-2 1-phenethyl-4-m-tolyl-piperidin-4-ol 
• 94913-96-9 1-phenethyl-4-phenyl-piperidin-4-ol 
• 64-52-8 acetic acid-(1-phenethyl-4-phenyl-[4]piperidyl ester) 
• 64-50-6 propionic acid-(1-phenethyl-4-phenyl-[4]piperidyl ester) 
• 2194-72-1 4-(4-fluoro-benzyl)-1-phenethyl-piperidin-4-ol 
• 67685-98-7 6-phenethyl-1-oxa-6-azaspiro[2.5]octane 
• 56658-03-8 4-[2-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-phenyl]-1-phenethyl-piperidin-4-ol 
• 91157-36-7 1-Phenethyl-4-pyrrolidin-1-yl-1,2,3,6-tetrahydro-pyridine 
• 118142-39-5 Morpholin-4-yl-(1-phenethyl-piperidin-4-ylidene)-amine 
• 118142-40-8 (1-Phenethyl-piperidin-4-ylidene)-pyridin-3-yl-amine 
• 118142-41-9 (1-Phenethyl-piperidin-4-ylidene)-pyridin-4-yl-amine 
• 118142-43-1 (6-Chloro-pyridin-3-yl)-(1-phenethyl-piperidin-4-ylidene)-amine 
• 118142-42-0 (2-Chloro-pyridin-3-yl)-(1-phenethyl-piperidin-4-ylidene)-amine 

Relevant articles and documents

ADJUVANTED CONJUGATE OPIOID VACCINE

The adjuvanted conjugate opioid vaccine described herein is a conjugate of a protein carrier and at least one opioid backbone component or hapten conjugated thereto, admixed with at least one adjuvant. Anti-opioid effects are demonstrated after administration of a vaccine made up of the CRM197 protein carrier linked to a FEN backbone, combined with adjuvants such as dmLT or LTA1.

Carbon isotope labeling of carbamates by late-stage [11C], [13C] and [14C]carbon dioxide incorporation

A general procedure for the late-stage [11C], [13C] and [14C]carbon isotope labeling of cyclic carbamates is reported. This protocol allows the incorporation of carbon dioxide, the primary source of carbon-14 and carbon-11 radioisotopes, in a direct, cost-effective and sustainable manner. A disconnection/reconnection strategy, involving ring opening/isotopic closure, was also implemented.

Design, synthesis and biological evaluation of novel copper-chelating acetylcholinesterase inhibitors with pyridine N-benzylpiperidine fragments

Cholinergic depletion is the direct cause of disability and dementia among AD patients. AChE is a classical and key target of cholinergic disorders. Some new inhibitors of AChE combining pyridine, acylhydrazone and N-benzylpiperidine fragments were developed in this work. The hit structure was optimized to yield the compound 21 with an IC50 value of 6.62 nM against AChE, while almost no inhibitory effect against BChE. ADMET predictions and PAMPA permeability evaluation showed good drug-like property. The higher activity with an intermediate alkyl chain substitution indicates a new binding mode of inhibitor with AChE. This finding provides new insights into the binding mechanism and is helpful for discovery of novel high-activity AChE inhibitors.

Nitro-Aldol Approach for Commercial Manufacturing of Fenspiride Hydrochloride

An efficient, short manufacturing process for fenspiride hydrochloride is reported. Nitro-aldol condensation is the key reaction in the developed process. Improved routes to key building blocks are demonstrated by expedient multikilogram production. Hazardous reactions are avoided. API produced following this new route meets the quality requirement NLT 99.70% purity by HPLC with any individual impurity NMT 0.10% with very good yield.

PEGYLATED OPIOID WITH LOW ADDICTIVE EFFECT

Provided in the present invention are a conjugate of polyethylene glycol and opioid as shown in general formula (I), and a pharmaceutical composition comprising the conjugate. By means of covalently bonding a plurality of opioids to a polyethylene glycol derivative, the present invention improves water solubility and pharmacokinetic property of the drug with a low addictive effect. ????????PEG-(X-OP)m?????(I)

A process for preparing 3 - methyl - 1 - phenethyl piperidine - 4 - one or 1 - phenethyl piperidine - 4 - one method

The invention discloses a method for preparing 3-mehtyl-1-phenethyl piperidine-4-ketone or 1-phenethyl piperidine-4-ketone. The method starts from easily-obtained 3-substituted pyridine-4-alcohol, sodium borohydride is selectively reduced into allyl alcohol after 3-substituted pyridine-4-alcohol forms quaternary ammonium together with phenethyl-2-halide, and 3-substitute-1-phenethyl piperidine-4-ketone is obtained then after isomerization. The synthetic method is easy, convenient to use, practical, high in operability and beneficial to further large-scale production.

N-phenethyl-4-aniline-based process for preparation of piperidines

The invention relates to a method for preparing N-phenethyl-4-phenylaminopiperidine. The method comprises the main steps of carrying out hydrogenation and amination on N-phenethyl-4-piperidone (structural formula as shown in a formula (II)) and aniline (structural formula as shown in a formula (III)) in ethanol in the presence of Raney Ni at the temperature of 50-100 DEG C so as to obtain the target product. The method for preparing N-phenethyl-4-phenylaminopiperidine has the advantages of cheap and available raw material, less byproduct, good product purity, high yield, low cost and the like.

An efficient, optimized synthesis of fentanyl and related analogs

The alternate and optimized syntheses of the parent opioid fentanyl and its analogs are described. The routes presented exhibit high-yielding transformations leading to these powerful analgesics after optimization studies were carried out for each synthetic step. The general three-step strategy produced a panel of four fentanyls in excellent yields (73-78%) along with their more commonly encountered hydrochloride and citric acid salts. The following strategy offers the opportunity for the gram-scale, efficient production of this interesting class of opioid alkaloids.

Novel symmetrical trans-bis-Schiff bases of N-substituted-4- piperidones: Synthesis, characterization, and preliminary antileukemia activity mensurations

A series of novel symmetrical trans-bis-Schiff bases (11a, 11b, 11c, 11d, 11e, 11f, 11g, 11h, 11i, 11j, 11k, 11l, 11m) were designed and prepared as novel anticancer analogues, with the trans-configuration confirmed by X-ray diffraction. Preliminary inhibitory effects of these compounds on CML K562 cell growth were investigated, and the potential analogue 11e showed an excellent anti-leukemia activity (IC50=6.35 μg/mL), which is higher than that of the clinical drug 5-fluorouracil (IC50=8.48 μg/mL). Complete assignments had been achieved for the title compounds by spectroscopic techniques, and their structure-activity relationships have been studied.

SUBSTITUTED 4-AMINO-PIPERIDINES

The present invention relates to new substituted 4-amino-piperidine opioid receptor modulators, pharmaceutical compositions thereof, and methods of use thereof